KaliVir Immunotherapeutics Appoints James M. Burke as Chief Medical Officer
KaliVir Announces Opening of GMP Cleanroom Facility
KaliVir Immunotherapeutics Announces FDA Clearance of IND for ASP1012
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Potent Therapeutic Activity for Oncolytic Therapy VET3-TGI at the American Association for Cancer Research (AACR) Annual Meeting
PITTSBURGH, Dec. 13, 2022 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that it has appointed the following experts to its clinical and scientific advisory boards:
PITTSBURGH, Nov. 1, 2022 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of Adina Pelusio, M.S., as Senior Vice President of Clinical Operations. Pelusio will be responsible for leading KaliVir's clinical development program and clinical operations.
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a...
KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development...
KaliVir Immunotherapeutics, Inc., a privately held biotechnology company focused on the discovery and development of next generation oncolytic vaccinia virus immunotherapies, today announced the appointment of Terry Hermiston, Ph.D., and Jon Wigginton, M.D., to the company's board of directors. Both gentleman bring decades of cancer immunotherapy development experience to KaliVir.
KaliVir Immunotherapeutics, Inc., a privately held biotechnology company focused on the discovery and development of next generation oncolytic vaccinia virus immunotherapies, today announced the appointment of Terry Hermiston, Ph.D., and Jon Wigginton, M.D., to the company's board of directors. Both gentleman bring decades of cancer immunotherapy development experience to KaliVir.